Expression of Decorin and Mimecan in cervical cancer and their impact on prognostic assessment

doi:10.11958/20250268

Abstract

Abstract:

Objective To explore the expression of core proteoglycans (Decorin) and osteoglycine (Mimecan) in cervical cancer and their relationship with the characteristics of clinical pathological traits and the prognosis of patients. Methods A total of 148 patients with cervical cancer who underwent surgical treatment in our hospital were selected. The expression levels of Decorin and Mimecan were determined by immunohistochemistry (IHC). The positive expression rates of Decorin and Mimecan in patients with different clinicopathological features were compared, and the correlation between the two was analyzed. Cox regression model was used to assess risk factors for death in patients with cervical cancer. Kaplan-Meier survival curve was used to compare the survival rates of patients with positive and negative Decorin and Mimecan expression. Results The positive expression levels of Decorin and Mimecan were both lower in cervical cancer tissue than those in adjacent tissue of cancer (20.0% vs. 75.0%, 28.3% vs. 63.3%, all P<0.05). The positive expression rates of Decorin and Mimecan were lower in patients with a tumor diameter ≥ 2 cm, FIGO stage Ⅲ-Ⅳ, lymph node metastasis and low tumor differentiation degree compared to those with a tumor diameter<2 cm, FIGO stage Ⅰ-Ⅱ, no lymph node metastasis and moderately to well tumor differentiation degree (P<0.05). There was a positive correlation of Decorin and Mimecan in cervical cancer tissue (r = 0.686, P<0.01). Multivariate Cox regression analysis confirmed that negative expression of Decorin (HR = 2.365, 95%CI: 1.236-4.525) and Mimecan (HR = 2.191, 95%CI: 1.322-3.631), FIGO stage Ⅲ-Ⅳ (HR = 1.747, 95%CI: 1.147-2.660) and low tumor differentiation degree (HR = 1.577, 95%CI: 1.035-2.404) were independent risk factors for mortality in cervical cancer patients (P<0.05). The 5-year survival rate of patients with positive Decorin and Mimecan expression was higher than those with negative expression (79.3% vs. 51.3%,73.8% vs. 50.0%), and the median survival time was prolonged (75 months vs. 60 months, 74 months vs. 60 months). Conclusion The positive expression rates of Decorin and Mimecan are reduced in cervical cancer tissue and may serve as potential biomarkers for prognostic evaluation of cervical cancer.

Key words: uterine cervical neoplasms, decorin, mimecan, clinical features, prognosis

CLC Number:

R737.2

Figures/Tables 7

References 27

[1]	JHA A K, MITHUN S, SHERKHANE U B, et al. Systematic review and meta-analysis of prediction models used in cervical cancer[J]. Artif Intell Med, 2023,139:102549. doi:10.1016/j.artmed.2023.102549.
[2]	杜晨旭, 公建庄, 张艺, 等. LINC01123通过miR-449a调控HGF/c-MET通路参与宫颈癌发生发展的分子机制[J]. 天津医药, 2022, 50(1):46-53.
	DU C X, GONG J Z, ZHANG Y, et al. The molecular mechanism of LINC01123 regulating the HGF/c-MET pathway through miR-449a in the occurrence and development of cervical cancer[J]. Tianjin Med J, 2022, 50(1):46-53. doi:10.11958/20211424.
[3]	LI M, ZHAO C, ZHAO Y, et al. Immunogenicity,efficacy,and safety of human papillomavirus vaccine: Data from China[J]. Front Immunol, 2023,14:1112750. doi:10.3389/fimmu.2023.1112750.
[4]	GUTIéRREZ-HOYA A, SOTO-CRUZ I. NK cell regulation in cervical cancer and strategies for immunotherapy[J]. Cells, 2021, 10(11):3104. doi:10.3390/cells10113104.
[5]	黄瑾. PD-1抑制剂联合含铂化疗±贝伐珠单抗治疗复发性或转移性宫颈癌的疗效及安全性分析[D]. 南昌: 南昌大学,2024:37.
	HUANG J. Efficacy and safety analysis of PD-1 inhibitors combined with platinum-based chemotherapy ± bevacizumab in the treatment of recurrent or metastatic cervical cancer[D]. Nanchang: Nanchang University, 2024:37. doi:10.27232/d.cnki.gnchu.2024.003749.
[6]	韩耀东, 陈鸿杰. 核心蛋白聚糖抗不同组织来源恶性肿瘤相关临床研究概况[J]. 甘肃中医药大学学报, 2024, 41(4):77-82.
	HAN Y D, CHEN H J. Overview of clinical research on the anti-malignant tumor effect of core protein polysaccharides from different tissue sources[J]. Journal of Gansu University of Traditional Chinese Medicine, 2024, 41(4):77-82. doi:10.16841/j.issn1003-8450.2024.04.15.
[7]	ZHANG W, GE Y, CHENG Q, et al. Decorin is a pivotal effector in the extracellular matrix and tumour microenvironment[J]. Oncotarget, 2018, 9(4):5480-5491. doi:10.18632/oncotarget.23869.
[8]	BOOTE C, MA Q, GOH K L. Age-dependent mechanical properties of tail tendons in wild-type and mimecan gene-knockout mice - a preliminary study[J]. J Mech Behav Biomed Mater, 2023,139:105672. doi:10.1016/j.jmbbm.2023.105672.
[9]	NULALI J, ZHAN M, ZHANG K, et al. Osteoglycin:an ECM factor regulating fibrosis and tumorigenesis[J]. Biomolecules, 2022, 12(11):1674. doi:10.3390/biom12111674.
[10]	ZHANG T, ZHUANG L, MUAIBATI M, et al. Identification of cervical cancer stem cells using single-cell transcriptomes of normal cervix, cervical premalignant lesions, and cervical cancer[J]. EBioMedicine, 2023,92:104612. doi:10.1016/j.ebiom.2023.104612.
[11]	GARG P, KRISHNA M, SUBBALAKSHMI A R, et al. Emerging biomarkers and molecular targets for precision medicine in cervical cancer[J]. Biochim Biophys Acta Rev Cancer, 2024, 1879(3): 189106. doi:10.1016/j.bbcan.2024.189106.
[12]	FAN H, HE Y, XIANG J, et al. ROS generation attenuates the anti-cancer effect of CPX on cervical cancer cells by inducing autophagy and inhibiting glycophagy[J]. Redox Biol, 2022,53:102339. doi:10.1016/j.redox.2022.102339.
[13]	SHI L, CHEN Z, OU J, et al. Pretheranostic agents with extraordinary NIRF/photoacoustic imaging performance and photothermal oncotherapy efficacy[J]. Acta Pharm Sin B, 2024, 14(12):5370-5387. doi:10.1016/j.apsb.2024.07.017.
[14]	DONG Y, ZHONG J, DONG L. The role of Decorin in autoimmune and inflammatory diseases[J]. J Immunol Res, 2022,2022:1283383. doi:10.1155/2022/1283383.
[15]	CHEN H, WANG Z, YANG N, et al. Decorin inhibits proliferation and metastasis in human bladder cancer cells by upregulating P21[J]. Medicine (Baltimore), 2022, 101(26):e29760. doi:10.1097/MD.0000000000029760.
[16]	LIN X, LI Q, HU L, et al. Apical papilla regulates dental follicle fate via the OGN-Hh pathway[J]. J Dent Res, 2023, 102(4):431-439. doi:10.1177/00220345221138517.
[17]	JIANG B, XIAO S, ZHANG S, et al. The miR-1290/OGN axis in ovarian cancer-associated fibroblasts modulates cancer cell proliferation and invasion[J]. J Ovarian Res, 2024, 17(1):52. doi:10.1186/s13048-024-01364-w.
[18]	LIU M, WANG W, PIAO S, et al. Relationship of biglycan and decorin expression with clinicopathological features and prognosis in patients with oral squamous cell carcinoma[J]. J Oral Pathol Med, 2023, 52(1):20-28. doi:10.1111/jop.13381.
[19]	樊东, 齐玉娟, 赵华栋. 骨诱导因子通过NF2/Hippo信号通路抑制甲状腺乳头状癌细胞增值和侵袭[J]. 山西医科大学学报, 2024, 55(3):269-279.
	FAN D, QI Y J, ZHAO H D. Bone inducing factors inhibit the proliferation and invasion of papillary thyroid carcinoma cells through NF2/Hippo signaling pathway[J]. Journal of Shanxi Medical University, 2024, 55(3):269-279. doi:10.13753/j.issn.1007-6611.
[20]	CONTINI C, MANCONI B, OLIANAS A, et al. Combined high-throughput proteomics and random forest machine-learning approach differentiates and classifies metabolic,immune,signaling and ECM intra-tumor heterogeneity of colorectal cancer[J]. Cells, 2024, 13(16):1311. doi:10.3390/cells13161311.
[21]	XIE C, MONDAL D K, ULAS M, et al. Oncosuppressive roles of decorin through regulation of multiple receptors and diverse signaling pathways[J]. Am J Physiol Cell Physiol, 2022, 322(3):C554-C566. doi:10.1152/ajpcell.00016.2022.
[22]	KARLSSON S, NYSTRÖM H. The extracellular matrix in colorectal cancer and its metastatic settling - Alterations and biological implications[J]. Crit Rev Oncol Hematol, 2022,175:103712. doi:10.1016/j.critrevonc.2022.103712.
[23]	HU X, LI Y Q, LI Q G, et al. Osteoglycin-induced VEGF inhibition enhances T lymphocytes infiltrating in colorectal cancer[J]. EBioMedicine, 2018, 34:35-45. doi:10.1016/j.ebiom.2018.07.021.
[24]	LI S, LU R, SHU L, et al. An integrated map of fibroblastic populations in human colon mucosa and cancer tissues[J]. Commun Biol, 2022, 5(1):1326. doi:10.1038/s42003-022-04298-5.
[25]	HJORTH M, EGAN C L, TELLES G D, et al. Decorin,an exercise-induced secretory protein,is associated with improved prognosis in breast cancer patients but does not mediate anti-tumorigenic tissue crosstalk in mice[J]. J Sport Health Sci, 2024,14:100991. doi:10.1016/j.jshs.2024.100991.
[26]	KAWAGUCHI T, YOSHIO S, SAKAMOTO Y, et al. Impact of decorin on the physical function and prognosis of patients with hepatocellular carcinoma[J]. J Clin Med, 2020, 9(4):936. doi:10.3390/jcm9040936.
[27]	XU T, ZHANG R, DONG M, et al. Osteoglycin(OGN)inhibits cell proliferation and invasiveness in breast cancer via PI3K/Akt/mTOR signaling pathway[J]. Onco Targets Ther, 2019, 12:10639-10650. doi:10.2147/OTT.S222967.

样本组织	n	Decorin		Mimecan
样本组织	n	阳性	阴性	阳性	阴性
癌旁组织	60	45（75.0）	15（25.0）	38（63.3）	22（36.7）
宫颈癌组织	60	12（20.0）	48（80.0）	17（28.3）	43（71.7）
χ²		36.391^＊＊		14.803^＊＊

样本组织	n	Decorin		Mimecan
样本组织	n	阳性	阴性	阳性	阴性
癌旁组织	60	45（75.0）	15（25.0）	38（63.3）	22（36.7）
宫颈癌组织	60	12（20.0）	48（80.0）	17（28.3）	43（71.7）
χ²		36.391^＊＊		14.803^＊＊

项目	n	Decorin阳性	χ²	Mimecan阳性	χ²
年龄
<60岁	69	13（18.8）	0.047	19（27.5）	0.045
≥60岁	79	16（20.3）	0.047	23（29.1）	0.045
妊娠次数
<2次	63	15（23.8）	1.237	23（36.5）	3.567
≥2次	85	14（16.5）	1.237	19（22.4）	3.567
肿瘤直径
≥2 cm	105	14（13.3）	8.993^＊＊	24（22.9）	5.420^＊
<2 cm	43	15（34.9）	8.993^＊＊	18（41.9）	5.420^＊
FIGO分期
Ⅰ—Ⅱ期	55	17（30.9）	7.112^＊＊	22（40.0）	5.816^＊
Ⅲ—Ⅳ期	93	12（12.9）	7.112^＊＊	20（21.5）	5.816^＊
淋巴结转移
有	86	11（12.8）	6.032^＊	19（22.1）	3.990^＊
无	62	18（29.0）	6.032^＊	23（37.1）	3.990^＊
分化程度
低分化	90	12（13.3）	5.715^＊	17（18.9）	10.175^＊＊
中高分化	58	17（29.3）	5.715^＊	25（43.1）	10.175^＊＊
肌层浸润深度
≥1/2	83	12（14.5）	3.165	19（22.9）	2.799
<1/2	65	17（26.2）	3.165	23（35.4）	2.799
组织学分型
腺癌	70	18（25.7）	3.157	24（34.3）	2.280
鳞癌	78	11（14.1）	3.157	18（23.1）	2.280

项目	n	Decorin阳性	χ²	Mimecan阳性	χ²
年龄
<60岁	69	13（18.8）	0.047	19（27.5）	0.045
≥60岁	79	16（20.3）	0.047	23（29.1）	0.045
妊娠次数
<2次	63	15（23.8）	1.237	23（36.5）	3.567
≥2次	85	14（16.5）	1.237	19（22.4）	3.567
肿瘤直径
≥2 cm	105	14（13.3）	8.993^＊＊	24（22.9）	5.420^＊
<2 cm	43	15（34.9）	8.993^＊＊	18（41.9）	5.420^＊
FIGO分期
Ⅰ—Ⅱ期	55	17（30.9）	7.112^＊＊	22（40.0）	5.816^＊
Ⅲ—Ⅳ期	93	12（12.9）	7.112^＊＊	20（21.5）	5.816^＊
淋巴结转移
有	86	11（12.8）	6.032^＊	19（22.1）	3.990^＊
无	62	18（29.0）	6.032^＊	23（37.1）	3.990^＊
分化程度
低分化	90	12（13.3）	5.715^＊	17（18.9）	10.175^＊＊
中高分化	58	17（29.3）	5.715^＊	25（43.1）	10.175^＊＊
肌层浸润深度
≥1/2	83	12（14.5）	3.165	19（22.9）	2.799
<1/2	65	17（26.2）	3.165	23（35.4）	2.799
组织学分型
腺癌	70	18（25.7）	3.157	24（34.3）	2.280
鳞癌	78	11（14.1）	3.157	18（23.1）	2.280

因素	β	SE	Wald χ²	P	HR	HR 95%CI
年龄	0.104	0.210	0.244	0.621	1.109	0.735~1.674
妊娠次数	0.153	0.211	0.524	0.469	1.165	0.770~1.763
肿瘤直径	0.006	0.209	0.001	0.976	1.006	0.668~1.516
FIGO分期	0.599	0.210	8.158	0.004	1.820	1.207~2.744
淋巴结转移	0.522	0.218	5.735	0.017	1.686	1.099~2.585
肿瘤分化程度	0.455	0.214	4.531	0.033	1.576	1.037~2.396
肌层浸润深度	0.043	0.210	0.041	0.840	1.044	0.691~1.576
组织学分型	0.098	0.209	0.221	0.638	1.103	0.732~1.662
Decorin	0.997	0.325	9.443	0.002	2.711	1.435~5.121
Mimecan	0.702	0.254	7.616	0.006	2.018	1.226~3.321